Literature DB >> 8774572

Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX.

H Barr1, N A Shepherd, A Dix, D J Roberts, W C Tan, N Krasner.   

Abstract

BACKGROUND: High-grade dysplasia in columnar-lined (Barrett's) oesophagus presents a difficult therapeutic dilemma. Choices for management are endoscopic surveillance to detect a cancer or oesophagectomy. One carries the risk of missing invasive cancer, the other carries worrying morbidity and mortality. We have used endoscopic photodynamic therapy to eradicate high-grade dysplasia.
METHODS: After the oral administration of 5-aminolaevulinic acid, the accumulation of the endogenously generated photosensitiser protoporphyrin IX was measured with quantitative fluorescence microscopy. Five patients with histologically confirmed high-grade dysplasia were treated with endoscopic photodynamic therapy with 630 nm laser light to activate the photosensitiser.
FINDINGS: Protoporphyrin IX accumulated in the dysplastic epithelium rather than the adjacent stroma. Selective necrosis of the dysplastic epithelium in columnar-lined oesophagus occurred after light activation. High-grade dysplasia was eradicated in all patients and squamous regeneration occurred after acid suppression with a protonpump inhibitor. There were no complications or recurrence of dysplasia after 26-44 months' endoscopic and histological follow-up. In two cases we saw non-dysplastic Barrett's epithelium underneath regenerative squamous mucosa.
INTERPRETATION: High-grade dysplasia in columnar-lined oesophagus can be eradicated by endoscopic photodynamic therapy with endogenously generated PpIX. Remaining non-dysplastic Barrett's epithelium will require surveillance, but overall the technique has interrupted or delayed the worsening of the dysplasia through to carcinoma. This technique may prevent the need for surgical excision in these patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774572     DOI: 10.1016/s0140-6736(96)03054-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  47 in total

1.  Ablation treatment for Barrett oesophagus: what depth of tissue destruction is needed?

Authors:  R Ackroyd; N J Brown; T J Stephenson; C J Stoddard; M W Reed
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

Review 2.  Photodynamic therapy.

Authors:  D C Shackley; C Whitehurst; N W Clarke; C Betts; J V Moore
Journal:  J R Soc Med       Date:  1999-11       Impact factor: 5.344

3.  Barrett's oesophagus and proton pump inhibitors: a pathological perspective.

Authors:  N A Shepherd
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

4.  Photoablation of Barret's esophagus.

Authors:  K K Wang
Journal:  J Gastrointest Surg       Date:  2000 Jul-Aug       Impact factor: 3.452

Review 5.  Barrett's oesophagus.

Authors:  R M Navaratnam; M C Winslet
Journal:  Postgrad Med J       Date:  1998-11       Impact factor: 2.401

Review 6.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 7.  Photodynamic therapy in the management of Barrett's esophagus with dysplasia.

Authors:  B F Overholt; M Panjehpour
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

8.  Barrett's esophagus: is dysplasia a reliable marker in surveillance after endoscopic treatment?

Authors:  M A Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-10

Review 9.  Endoscopic ablation of Barrett's esophagus.

Authors:  M B Fennerty
Journal:  Curr Gastroenterol Rep       Date:  1999-06

10.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.